8-K: Bio-Path Holdings Enters At-The-Market Offering Agreement for Up to $2 Million

Bio-Path Holdings has entered into an agreement with H.C. Wainwright & Co. to sell up to $2 million of its common stock through an at-the-market offering.

Summary

• Bio-Path Holdings has signed an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell shares of its common stock.
• The company may offer and sell shares from time to time through Wainwright, acting as a sales agent.
• Bio-Path is not obligated to sell any shares under this agreement.
• Wainwright will use commercially reasonable efforts to sell shares based on the company's instructions, including any price, time, or size limits.
• The shares will be sold at market prices, or through privately negotiated transactions with prior written approval from Bio-Path.
• Wainwright will receive a commission of 3.0% of the gross proceeds from each sale of shares.
• The company has agreed to provide customary indemnification and contribution rights to Wainwright and reimburse certain expenses.
• The sales will be made under a previously filed registration statement, with a related prospectus supplement filed on April 4, 2024, for an aggregate offering price of up to $2,000,000.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The ATM offering provides financial flexibility, but also introduces potential dilution and costs. It's a standard financial move, not particularly exciting or concerning.

Positives

• The ATM agreement provides Bio-Path with a flexible way to raise capital.
• The company is not obligated to sell shares, giving them control over the timing and amount of any offering.
• The agreement allows for sales at market prices, potentially maximizing proceeds.
• The company has the option to sell shares through privately negotiated transactions.

Negatives

• The company will incur a 3.0% commission on gross proceeds from each sale of shares.
• There is no guarantee that the company will be able to sell all of the shares offered.
• The offering could potentially dilute existing shareholders.

Risks

• The company may not be able to sell all of the shares offered under the ATM agreement.
• The market price of the company's stock could be negatively impacted by the offering.
• The company's stock price could be diluted by the issuance of new shares.
• There is a risk that the company may not be able to raise the full $2 million.

Future Outlook

The company may offer and sell shares from time to time through Wainwright, but is not obligated to sell any shares under the agreement. The company will use the net proceeds from the sale of the shares in the manner set forth in the prospectus.

Management Comments

• The company is not obligated to sell any shares under the ATM Agreement.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. This allows companies to sell shares gradually into the market, reducing the risk of significant price drops. This is a common strategy for companies that need to raise capital without the need for a large, dilutive secondary offering.

Comparison to Industry Standards

• The 3.0% commission is within the typical range for at-the-market offerings.
• The $2 million offering size is relatively small, which is common for smaller biotech companies.
• Many biotech companies use ATM offerings to fund ongoing research and development activities.
• Comparable companies that have used ATM offerings include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company will have additional capital to fund its operations.
• The company's financial position may be strengthened by the capital raise.

Next Steps

• Bio-Path Holdings may sell shares of its common stock through H.C. Wainwright & Co., LLC.
• The company will monitor market conditions and its capital needs to determine the timing and amount of any sales.
• The company will file required reports with the SEC regarding the sales of shares.

Key Dates

Keywords

At-The-Market Offering, ATM, Capital Raise, Common Stock, H.C. Wainwright, Securities Offering, Bio-Path Holdings, Equity Financing